Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics’ Degrader Platform (NRIX)?

Nurix Therapeutics recently reported Phase 1 data showing its BTK degrader bexobrutideg (NX-5948) achieved a 75% objective response rate in patients with relapsed or refractory Waldenström macroglobulinemia, with mostly low-grade side effects supporting further development. This early signal suggests Nurix’s targeted protein degradation platform could offer a differentiated approach in a difficult-to-treat blood cancer setting. Next, we’ll explore how this promising Waldenström...